{"id":"https://openalex.org/W3170935260","doi":"https://doi.org/10.1200/jco.2021.39.15_suppl.e21548","title":"Robust prediction of response to immunotherapy in a mixed cohort of previously treated and immunotherapy-naive melanoma patients.","display_name":"Robust prediction of response to immunotherapy in a mixed cohort of previously treated and immunotherapy-naive melanoma patients.","publication_year":2021,"publication_date":"2021-05-20","ids":{"openalex":"https://openalex.org/W3170935260","doi":"https://doi.org/10.1200/jco.2021.39.15_suppl.e21548","mag":"3170935260"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2021.39.15_suppl.e21548","doi":"https://doi.org/10.1200/jco.2021.39.15_suppl.e21548","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2021.39.15_suppl.e21548","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5007253388","display_name":"Charles W. Abbott","orcid":"https://orcid.org/0000-0002-3837-6471","observed_orcids":["https://orcid.org/0000-0002-3837-6471"]},"institutions":[{"id":"https://openalex.org/I4210119510","display_name":"Personalis (United States)","ror":"https://ror.org/0303drj82","country_code":"US","type":"company","lineage":["https://openalex.org/I4210119510"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charles Abbott","raw_affiliation_strings":["Personalis, Inc., Menlo Park, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Personalis, Inc., Menlo Park, CA;","institution_ids":["https://openalex.org/I4210119510"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003140445","display_name":"Lee McDaniel","orcid":"https://orcid.org/0000-0003-1036-613X","observed_orcids":["https://orcid.org/0000-0003-1036-613X"]},"institutions":[{"id":"https://openalex.org/I4210119510","display_name":"Personalis (United States)","ror":"https://ror.org/0303drj82","country_code":"US","type":"company","lineage":["https://openalex.org/I4210119510"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lee McDaniel","raw_affiliation_strings":["Personalis, Inc., Menlo Park, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Personalis, Inc., Menlo Park, CA;","institution_ids":["https://openalex.org/I4210119510"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060460344","display_name":"Rachel Marty Pyke","orcid":"https://orcid.org/0000-0001-8967-7867","observed_orcids":["https://orcid.org/0000-0001-8967-7867"]},"institutions":[{"id":"https://openalex.org/I4210119510","display_name":"Personalis (United States)","ror":"https://ror.org/0303drj82","country_code":"US","type":"company","lineage":["https://openalex.org/I4210119510"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rachel Pyke","raw_affiliation_strings":["Personalis, Inc., Menlo Park, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Personalis, Inc., Menlo Park, CA;","institution_ids":["https://openalex.org/I4210119510"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111779521","display_name":"\u00c9ric Levy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210119510","display_name":"Personalis (United States)","ror":"https://ror.org/0303drj82","country_code":"US","type":"company","lineage":["https://openalex.org/I4210119510"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric Levy","raw_affiliation_strings":["Personalis, Inc., Menlo Park, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Personalis, Inc., Menlo Park, CA;","institution_ids":["https://openalex.org/I4210119510"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032592883","display_name":"F\u00e1bio C. P. Navarro","orcid":"https://orcid.org/0000-0002-5640-9070","observed_orcids":["https://orcid.org/0000-0002-5640-9070"]},"institutions":[{"id":"https://openalex.org/I4210119510","display_name":"Personalis (United States)","ror":"https://ror.org/0303drj82","country_code":"US","type":"company","lineage":["https://openalex.org/I4210119510"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Fabio Navarro","raw_affiliation_strings":["Personalis, Inc., Menlo Park, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Personalis, Inc., Menlo Park, CA;","institution_ids":["https://openalex.org/I4210119510"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086660741","display_name":"Simo V. Zhang","orcid":"https://orcid.org/0000-0003-2154-2549","observed_orcids":["https://orcid.org/0000-0003-2154-2549"]},"institutions":[{"id":"https://openalex.org/I4210119510","display_name":"Personalis (United States)","ror":"https://ror.org/0303drj82","country_code":"US","type":"company","lineage":["https://openalex.org/I4210119510"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Simo V. Zhang","raw_affiliation_strings":["Personalis, Inc., Menlo Park, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Personalis, Inc., Menlo Park, CA;","institution_ids":["https://openalex.org/I4210119510"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100378656","display_name":"Jing Wang","orcid":"https://orcid.org/0000-0003-1580-1356","observed_orcids":["https://orcid.org/0000-0003-1580-1356","https://orcid.org/0009-0009-7012-5216","https://orcid.org/0000-0002-1980-539X"]},"institutions":[{"id":"https://openalex.org/I4210119510","display_name":"Personalis (United States)","ror":"https://ror.org/0303drj82","country_code":"US","type":"company","lineage":["https://openalex.org/I4210119510"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jing Wang","raw_affiliation_strings":["Personalis, Inc., Menlo Park, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Personalis, Inc., Menlo Park, CA;","institution_ids":["https://openalex.org/I4210119510"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085782279","display_name":"Rena McClory","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210119510","display_name":"Personalis (United States)","ror":"https://ror.org/0303drj82","country_code":"US","type":"company","lineage":["https://openalex.org/I4210119510"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rena McClory","raw_affiliation_strings":["Personalis, Inc., Menlo Park, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Personalis, Inc., Menlo Park, CA;","institution_ids":["https://openalex.org/I4210119510"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024120181","display_name":"Michael P. Snyder","orcid":"https://orcid.org/0000-0003-0784-7987","observed_orcids":["https://orcid.org/0000-0003-0784-7987"]},"institutions":[{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Snyder","raw_affiliation_strings":["Stanford University, Stanford, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Stanford University, Stanford, CA;","institution_ids":["https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109602066","display_name":"Sekwon Jang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800468613","display_name":"Inova Fairfax Hospital","ror":"https://ror.org/0212h5y77","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I116530498","https://openalex.org/I2800468613"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sekwon Jang","raw_affiliation_strings":["Inova Schar Cancer Institute, Fairfax, VA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Inova Schar Cancer Institute, Fairfax, VA;","institution_ids":["https://openalex.org/I2800468613"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082247454","display_name":"Sean Michael Boyle","orcid":"https://orcid.org/0000-0002-4402-8449","observed_orcids":["https://orcid.org/0000-0002-4402-8449"]},"institutions":[{"id":"https://openalex.org/I4210119510","display_name":"Personalis (United States)","ror":"https://ror.org/0303drj82","country_code":"US","type":"company","lineage":["https://openalex.org/I4210119510"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sean Michael Boyle","raw_affiliation_strings":["Personalis, Inc., Menlo Park, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Personalis, Inc., Menlo Park, CA;","institution_ids":["https://openalex.org/I4210119510"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5067420630","display_name":"Richard Chen","orcid":"https://orcid.org/0000-0002-2842-4476","observed_orcids":["https://orcid.org/0000-0002-2842-4476"]},"institutions":[{"id":"https://openalex.org/I4210119510","display_name":"Personalis (United States)","ror":"https://ror.org/0303drj82","country_code":"US","type":"company","lineage":["https://openalex.org/I4210119510"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard Chen","raw_affiliation_strings":["Personalis, Inc., Menlo Park, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Personalis, Inc., Menlo Park, CA;","institution_ids":["https://openalex.org/I4210119510"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"39","issue":"15_suppl","first_page":"e21548","last_page":"e21548"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.9769999980926514},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.9589999914169312},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.9649999737739563},{"id":"https://openalex.org/keywords/immunotherapy-response-prediction","display_name":"immunotherapy response prediction","score":0.906000018119812},{"id":"https://openalex.org/keywords/neoantigens","display_name":"neoantigens","score":0.8100000023841858},{"id":"https://openalex.org/keywords/tumor-mutational-burden","display_name":"tumor mutational burden","score":0.6039999723434448},{"id":"https://openalex.org/keywords/hla-loss-of-heterozygosity","display_name":"HLA loss of heterozygosity","score":0.8809999823570251},{"id":"https://openalex.org/keywords/tcr-repertoire","display_name":"T cell receptor repertoire","score":0.6169999837875366},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.8799999952316284},{"id":"https://openalex.org/keywords/immune-resistance-mechanisms","display_name":"immune resistance mechanisms","score":0.5210000276565552},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.7599999904632568},{"id":"https://openalex.org/keywords/previously-treated-patients","display_name":"previously treated patients","score":0.550000011920929},{"id":"https://openalex.org/keywords/immunotherapy-naive-patients","display_name":"immunotherapy-naive patients","score":0.6499999761581421},{"id":"https://openalex.org/keywords/sherpa","display_name":"Sherpa","score":0.5180000066757202},{"id":"https://openalex.org/keywords/dash","display_name":"DASH","score":0.9089999794960022}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7532635927200317},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.6287387013435364},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.5201535820960999},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5155298709869385},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.5084854364395142},{"id":"https://openalex.org/C10590036","wikidata":"https://www.wikidata.org/wiki/Q417664","display_name":"Exome","level":5,"score":0.48552727699279785},{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.4448367953300476},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.43260428309440613},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.4183313846588135},{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.4134588837623596},{"id":"https://openalex.org/C16671776","wikidata":"https://www.wikidata.org/wiki/Q5420592","display_name":"Exome sequencing","level":4,"score":0.4081882834434509},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.35386550426483154},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3204309642314911},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.29823940992355347},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.18732118606567383},{"id":"https://openalex.org/C127716648","wikidata":"https://www.wikidata.org/wiki/Q104053","display_name":"Phenotype","level":3,"score":0.178369402885437},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.11976155638694763},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.11683106422424316},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.08996650576591492}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2021.39.15_suppl.e21548","doi":"https://doi.org/10.1200/jco.2021.39.15_suppl.e21548","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2021.39.15_suppl.e21548","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3188480132","https://openalex.org/W4286297605","https://openalex.org/W4308398268","https://openalex.org/W3082610081","https://openalex.org/W2887187316","https://openalex.org/W2991341799","https://openalex.org/W3088170039","https://openalex.org/W3032399294","https://openalex.org/W4200412346","https://openalex.org/W3215371632"],"abstract_inverted_index":{"e21548":[0],"Background:":[1],"While":[2],"immune":[3,28],"checkpoint":[4],"blockade":[5],"(ICB)":[6],"has":[7],"become":[8],"a":[9,35,86,95,149,233,277,302,330],"pillar":[10],"of":[11,89,167,221,265,280,293,306,316,349],"cancer":[12],"treatment,":[13,327],"biomarkers":[14,333,358],"that":[15,34,193,299,334,343,355],"consistently":[16],"predict":[17,47,338],"patient":[18,350],"response":[19,29,49,82,237,266,308],"remain":[20],"elusive":[21],"due":[22],"to":[23,30,70,79,83,147,173,216,248,318],"the":[24,245,260,269,313],"complex":[25,314],"mechanisms":[26,44,172],"driving":[27],"tumors.":[31],"We":[32,159,191,241,352],"hypothesized":[33],"multi-dimensional":[36],"approach":[37],"modeling":[38,166],"both":[39,268],"tumor":[40,81,99,123,139,367,377],"and":[41,100,106,117,133,138,169,185,199,223,255,282],"immune-related":[42,170],"molecular":[43],"would":[45],"better":[46],"ICB":[48,307],"than":[50,204],"simpler":[51],"mutation-focused":[52],"biomarkers.":[53],"Methods:":[54],"Pre-treatment":[55],"samples":[56],"from":[57,181],"51":[58],"unresectable,":[59],"stage":[60],"III/IV":[61],"melanoma":[62],"patients":[63,294],"who":[64],"underwent":[65],"anti-PD-1":[66],"therapy":[67],"were":[68,77,144,287],"characterized":[69],"assess":[71],"factors":[72],"influencing":[73],"response.":[74,339,351],"RECIST":[75],"criteria":[76],"used":[78,242],"evaluate":[80],"therapy,":[84],"with":[85,164,236,326,365],"median":[87],"follow-up":[88],"24":[90],"months.":[91],"For":[92],"each":[93,156],"patient,":[94],"single":[96],"paired":[97],"FFPE":[98],"normal":[101],"blood":[102],"sample":[103],"was":[104,179,262],"collected":[105],"profiled":[107],"using":[108,374],"Personalis\u2019":[109],"ImmunoID":[110],"NeXT":[111],"Platform;":[112],"an":[113,290],"augmented":[114],"exome/transcriptome":[115],"platform":[116],"analysis":[118],"pipeline":[119],"which":[120],"produces":[121],"comprehensive":[122,366],"mutation":[124],"information,":[125],"gene":[126],"expression":[127],"profiling,":[128,137],"neoantigen":[129,151,188],"characterization,":[130],"HLA":[131,218],"typing":[132],"LOH,":[134],"TCR":[135],"repertoire":[136],"microenvironment":[140],"profiling.":[141],"These":[142,285],"data":[143,356],"then":[145],"integrated":[146],"form":[148],"composite":[150],"presentation":[152],"score":[153,177],"(NEOPS)":[154],"for":[155,332],"patient.":[157],"Results:":[158],"demonstrate":[160,342,354],"increasing":[161],"predictive":[162,257,264],"power":[163],"deeper":[165],"neoantigens":[168],"resistance":[171,228,317],"ICB.":[174],"Neoantigen":[175],"burden":[176],"(NBS)":[178],"derived":[180],"SHERPA,":[182],"our":[183,370],"exome":[184],"transcriptome":[186],"integrative":[187],"prediction":[189],"model.":[190],"found":[192],"NBS":[194],"more":[195,263,336],"significantly":[196,346],"stratified":[197],"responders":[198],"non-responders":[200],"(P":[201,207],"=":[202,208,239,296],"0.016)":[203],"TMB":[205],"alone":[206],"0.049).":[209],"A":[210],"broader":[211],"score,":[212],"NEOPS,":[213],"incorporated":[214],"DASH,":[215],"capture":[217],"allele-specific":[219],"loss":[220],"heterozygosity":[222],"additional":[224],"antigen":[225],"presenting":[226],"machinery":[227],"mechanisms.":[229],"NEOPS":[230,250,300,344,360],"consequently":[231],"demonstrated":[232],"stronger":[234],"association":[235],"(p":[238],"0.002).":[240],"area":[243],"under":[244],"curve":[246],"(AUC)":[247],"benchmark":[249],"performance":[251],"against":[252],"established":[253],"mutational":[254],"transcriptomic":[256],"models,":[258],"demonstrating":[259],"model":[261],"in":[267,276,289,309,369],"treatment":[270],"naive":[271],"setting,":[272],"as":[273,275,320,322],"well":[274,321],"mixed":[278],"cohort":[279,292,372],"treatment-naive":[281],"experienced":[283],"patients.":[284],"findings":[286],"confirmed":[288],"independent":[291],"(n":[295],"110),":[297],"suggesting":[298],"is":[301,329],"robust,":[303],"novel":[304],"biomarker":[305],"melanoma.":[310],"Conclusions:":[311],"Given":[312],"nature":[315],"immunotherapy,":[319],"potential":[323],"toxicities":[324],"associated":[325],"there":[328],"need":[331],"can":[335,345,361],"accurately":[337],"Here":[340],"we":[341],"improve":[347],"stratification":[348],"also":[353],"intensive":[357],"like":[359],"be":[362],"clinically":[363],"practical,":[364],"profiling":[368],"clinical":[371],"achieved":[373],"very":[375],"limited":[376],"tissue.":[378]},"counts_by_year":[],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2021-06-22T00:00:00"}